Literature DB >> 25434388

Time window for postoperative reactive enhancement after resection of brain tumors: less than 72 hours.

Stephanie Lescher1, Sonja Schniewindt, Alina Jurcoane, Christian Senft, Elke Hattingen.   

Abstract

OBJECT: Early postoperative MRI within 72 hours after brain tumor surgery is commonly used to assess residual contrast-enhancing tumor. The 72-hour window is commonly accepted because previous 1.5-T MRI studies have not found confounding postoperative reactive contrast enhancement in this time frame. The sensitivity to detect contrast enhancement increases with the field strengths. Therefore, the authors aimed to assess whether the 72-hour window is also appropriate for the MRI scanner with a field strength of 3 T.
METHODS: The authors retrospectively analyzed findings on early postsurgical MR images acquired in 46 patients treated for high-grade gliomas. They performed 3-T MRI within 7 days before surgery and within 72 hours thereafter. The appearance of enhancement was categorized as postoperative reactive enhancement or tumoral enhancement by comparison with the pattern and location of presurgical enhancing tumor.
RESULTS: Postoperative reactive enhancement was present in 15 patients (32.6%). This enhancement, not seen on presurgical MRI, had a marginal or leptomeningeal/dural pattern. In 13 patients (28.3%) postsurgical enhancement was found within the first 72 postoperative hours, with the earliest seen 22:57 hours after surgery. Subsequent MR scans in patients with postoperative reactive enhancement did not reveal tumor recurrence in these regions.
CONCLUSIONS: Postoperative reactive enhancement earlier than 72 hours after brain tumor surgery can be expected in about one-third of the cases in which a 3-T scanner is used. This might be due to the higher enhancement-to-brain contrast at higher field strengths. Therefore, the time window of 72 hours does not prevent reactive enhancement, which, however, can be recognized as such comparing it with presurgical enhancing tumor.

Entities:  

Keywords:  MRI; brain tumors; iMRI = intraoperative MRI; postoperative enhancement; surgery; time window

Mesh:

Year:  2014        PMID: 25434388     DOI: 10.3171/2014.9.FOCUS14479

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  18 in total

Review 1.  European Society for Paediatric Oncology (SIOPE) MRI guidelines for imaging patients with central nervous system tumours.

Authors:  Shivaram Avula; Andrew Peet; Giovanni Morana; Paul Morgan; Monika Warmuth-Metz; Tim Jaspan
Journal:  Childs Nerv Syst       Date:  2021-05-10       Impact factor: 1.475

2.  Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trials.

Authors:  Rebecca A Packer; John H Rossmeisl; Michael S Kent; John F Griffin; Christina Mazcko; Amy K LeBlanc
Journal:  Vet Radiol Ultrasound       Date:  2018-03-09       Impact factor: 1.363

3.  Frequency and Evolution of New Postoperative Enhancement on 3 Tesla Intraoperative and Early Postoperative Magnetic Resonance Imaging.

Authors:  Nityanand Miskin; Prashin Unadkat; Michael E Carlton; Alexandra J Golby; Geoffrey S Young; Raymond Y Huang
Journal:  Neurosurgery       Date:  2020-08-01       Impact factor: 4.654

4.  Predictive Value of MRI in Diagnosing Brain AVM Recurrence after Angiographically Documented Exclusion in Children.

Authors:  A Jhaveri; A Amirabadi; P Dirks; A V Kulkarni; M M Shroff; N Shkumat; T Krings; V M Pereira; V Rea; P Muthusami
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

Review 5.  Standard clinical approaches and emerging modalities for glioblastoma imaging.

Authors:  Joshua D Bernstock; Sam E Gary; Neil Klinger; Pablo A Valdes; Walid Ibn Essayed; Hannah E Olsen; Gustavo Chagoya; Galal Elsayed; Daisuke Yamashita; Patrick Schuss; Florian A Gessler; Pier Paolo Peruzzi; Asim K Bag; Gregory K Friedman
Journal:  Neurooncol Adv       Date:  2022-05-26

6.  Imaging and diagnostic advances for intracranial meningiomas.

Authors:  Raymond Y Huang; Wenya Linda Bi; Brent Griffith; Timothy J Kaufmann; Christian la Fougère; Nils Ole Schmidt; Jöerg C Tonn; Michael A Vogelbaum; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Ian F Dunn
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

7.  Comparison of intraoperative and post-operative 3-T MRI performed at 24-72 h following brain tumour resection in children.

Authors:  Shivaram Avula; Tim Jaspan; Barry Pizer; Benedetta Pettorini; Deborah Garlick; Dawn Hennigan; Conor Mallucci
Journal:  Neuroradiology       Date:  2021-02-25       Impact factor: 2.804

8.  Pseudo-continuous arterial spin labelling shows high diagnostic performance in the detection of postoperative residual lesion in hyper-vascularised adult brain tumours.

Authors:  Clara Cohen; Bruno Law-Ye; Didier Dormont; Delphine Leclercq; Laurent Capelle; Marc Sanson; Damien Galanaud; Nadya Pyatigorskaya
Journal:  Eur Radiol       Date:  2020-01-21       Impact factor: 5.315

9.  Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome.

Authors:  Aikaterini Kotrotsou; Ahmed Elakkad; Jia Sun; Ginu A Thomas; Dongni Yang; Srishti Abrol; Wei Wei; Jeffrey S Weinberg; Ali S Bakhtiari; Moritz F Kircher; Markus M Luedi; John F de Groot; Raymond Sawaya; Ashok J Kumar; Pascal O Zinn; Rivka R Colen
Journal:  J Neurooncol       Date:  2018-04-04       Impact factor: 4.130

10.  Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma.

Authors:  Daniel Dubinski; Sae-Yeon Won; Florian Gessler; Johanna Quick-Weller; Bedjan Behmanesh; Simon Bernatz; Marie-Therese Forster; Kea Franz; Karl-Heinz Plate; Volker Seifert; Patrick N Harter; Christian Senft
Journal:  J Neurooncol       Date:  2018-01-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.